Updated data from the Phase III TALAPRO-2 trial show that the combination of Talzenna (talazoparib) and Xtandi (enzalutamide) ...

Treatment (Rx) patterns and attrition rates in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Real world comparison of time-to-next-treatment (TTNT), ...

Recently, licensed and emerging treatments for metastatic ... a view to maximize survival as well. This article provides an overview of developments in advanced prostate cancer and considers ...

Forms of localized treatment have potential to positively impact the survival rate and prognosis of men diagnosed with certain forms of metastatic prostate cancer. Most prostate cancer survivors ...

Radiotherapy and surgery are curative treatment options for localized prostate cancer (PCa) with a 5-year survival rate of nearly 100%. Once PCa cells spread into distant organs, such as bone, the ...

Darolutamide may offer greater benefits than enzalutamide or apalutamide for Black and White patients with non-metastatic ...

External beam radiation therapy with or without short-term androgen deprivation showed 15-year survival benefits for ...

Overall survival between veterans with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone with kidney disease.

“Survival rates in metastatic castration-resistant prostate cancer are poor due to the advanced and aggressive stage of the disease. Today’s results demonstrate the potential for TALZENNA in ...

Real-world data support trial data on the use of lutetium-177 PSMA-617 in patients with PSMA-positive, metastatic castration-resistant prostate cancer.

Investigators report that estradiol works as well as luteinizing hormone–releasing hormone agonists for testosterone suppression and have a much better side-effect profile.

Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate ...